Skip to main content
Top
Published in: PharmacoEconomics 7/2002

01-06-2002 | Review Article

Standardisation of Costs

The Dutch Manual for Costing in Economic Evaluations

Authors: Jan B. Oostenbrink, Marc A. Koopmanschap, Frans F. H. Rutten

Published in: PharmacoEconomics | Issue 7/2002

Login to get access

Abstract

The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements for studies to be considered when deciding on the reimbursement of new medical therapies. Recently, the Dutch Manual for Costing: Methods and Standard Costs for Economic Evaluations in Health Care (further referred to as ‘the manual’) has been published, in addition to the Dutch guidelines for pharmacoeconomic research. The objectives of this article are to describe the main content of the manual and to discuss some key issues of the manual in relation to the standardisation of costs.
The manual introduces a six-step procedure for costing. These steps concern: (i) the scope of the study; (ii) the choice of cost categories; (iii) the identification of units; (iv) the measurement of resource use; (v) the monetary valuation of units; and (vi) the calculation of unit costs. Each step consists of a number of choices and these together define the approach taken. In addition to a description of the costing process, five key issues regarding the standardisation of costs are distinguished. These are the use of basic principles, methods for measurement and valuation, standard costs (average prices of healthcare services), standard values (values that can be used within unit cost calculations), and the reporting of outcomes. The use of the basic principles, standard values and minimal requirements for reporting outcomes, as defined in the manual, are obligatory in studies that support submissions to acquire reimbursement for new pharmaceuticals. Whether to use standard costs, and the choice of a particular method to measure or value costs, is left mainly to the investigator, depending on the specific study setting.
In conclusion, several instruments are available to increase standardisation in costing methodology among studies. These instruments have to be used in such a way that a balance is found between standardisation and the specific setting in which a study is performed. The way in which the Dutch manual tries to reach this balance can serve as an illustration for other countries.
Literature
1.
go back to reference Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159–68PubMedCrossRef Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159–68PubMedCrossRef
2.
go back to reference Haycox A, Walley T. Pharmacoeconomics: evaluating the evaluators. Br J Clin Pharmacol 1997; 43: 451–6PubMedCrossRef Haycox A, Walley T. Pharmacoeconomics: evaluating the evaluators. Br J Clin Pharmacol 1997; 43: 451–6PubMedCrossRef
3.
go back to reference Drummond MF, Brandt A, Luce BR, et al. Standardizing methodologies for economic evaluation in health care. Int J Technol Assess Health Care 1993; 9 (1): 26–36PubMedCrossRef Drummond MF, Brandt A, Luce BR, et al. Standardizing methodologies for economic evaluation in health care. Int J Technol Assess Health Care 1993; 9 (1): 26–36PubMedCrossRef
4.
go back to reference Rovira J. Standardization of the economic evaluation of health technologies, European developments. Med Care 1996; 34 (12 Suppl.): DS182–8PubMed Rovira J. Standardization of the economic evaluation of health technologies, European developments. Med Care 1996; 34 (12 Suppl.): DS182–8PubMed
5.
6.
go back to reference Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997 Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997
7.
go back to reference Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. 1st ed. New York (NY): Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. 1st ed. New York (NY): Oxford University Press, 1996
8.
go back to reference Langley PC. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (4): 341–52PubMedCrossRef Langley PC. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (4): 341–52PubMedCrossRef
9.
go back to reference Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (6): 535–59PubMedCrossRef Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (6): 535–59PubMedCrossRef
10.
go back to reference Jacobs P, Bachynsky J, Baladi J-F. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8 (3): 182–9PubMedCrossRef Jacobs P, Bachynsky J, Baladi J-F. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8 (3): 182–9PubMedCrossRef
11.
go back to reference Rovira J, Antonanzas F. Economic analysis of health technologies and programmes. Pharmacoeconomics 1995; 8 (3): 245–52PubMedCrossRef Rovira J, Antonanzas F. Economic analysis of health technologies and programmes. Pharmacoeconomics 1995; 8 (3): 245–52PubMedCrossRef
12.
go back to reference Commonwealth Department of Health, Housing, Local Government and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department of Health, Housing, Local Government and Community Services, 1993 Commonwealth Department of Health, Housing, Local Government and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department of Health, Housing, Local Government and Community Services, 1993
13.
go back to reference Baladi JF. A guidance document for the costing process. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1996 Baladi JF. A guidance document for the costing process. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1996
14.
go back to reference Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for costing: methods and standard costs for economic evaluations in health care [in Dutch]. Amstelveen: College voor zorgverzekeringen, 2000 Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for costing: methods and standard costs for economic evaluations in health care [in Dutch]. Amstelveen: College voor zorgverzekeringen, 2000
15.
go back to reference Riteco JA, de Heij LJM, van Luijn JCF, et al. Dutch guidelines for pharmacoeconomic research. Amstelveen: College Voor Zorgverzekeringen, 1999 Riteco JA, de Heij LJM, van Luijn JCF, et al. Dutch guidelines for pharmacoeconomic research. Amstelveen: College Voor Zorgverzekeringen, 1999
16.
go back to reference Jacobs P, Baladi J-F. Biases in cost measurement for economic evaluation studies in health care. Health Econ 1996; 5: 525–9PubMedCrossRef Jacobs P, Baladi J-F. Biases in cost measurement for economic evaluation studies in health care. Health Econ 1996; 5: 525–9PubMedCrossRef
17.
go back to reference Goeree R, Gafni A, Hannah M, et al. Hospital selection for unit cost estimates in multicentre economic evaluations; does the choice of hospitals make a difference. Pharmacoeconomics 1999; 15: 561–72PubMedCrossRef Goeree R, Gafni A, Hannah M, et al. Hospital selection for unit cost estimates in multicentre economic evaluations; does the choice of hospitals make a difference. Pharmacoeconomics 1999; 15: 561–72PubMedCrossRef
18.
go back to reference Horngren CT. Cost accounting. 5th ed. Englewood Cliffs (NJ): Prentice-Hall, 1982 Horngren CT. Cost accounting. 5th ed. Englewood Cliffs (NJ): Prentice-Hall, 1982
19.
go back to reference Dutch Ministry of Finance. Textbook financial governmental information and administration. The Hague: Dutch Ministry of Finance, 1995 Dutch Ministry of Finance. Textbook financial governmental information and administration. The Hague: Dutch Ministry of Finance, 1995
20.
go back to reference Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997 Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997
21.
go back to reference Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995 Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995
22.
go back to reference Brouwer WBF, Koopmanschap MA, Rutten FFH. Patient and informal caregiver time in cost-effectiveness analysis: a response to the recommendations of the Washington Panel. Int J Technol Assess Health Care 1998; 14 (3): 505–13PubMedCrossRef Brouwer WBF, Koopmanschap MA, Rutten FFH. Patient and informal caregiver time in cost-effectiveness analysis: a response to the recommendations of the Washington Panel. Int J Technol Assess Health Care 1998; 14 (3): 505–13PubMedCrossRef
23.
go back to reference Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997; 11 (5): 385–8PubMedCrossRef Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997; 11 (5): 385–8PubMedCrossRef
24.
go back to reference Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89PubMedCrossRef Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89PubMedCrossRef
25.
go back to reference Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005–10PubMedCrossRef Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005–10PubMedCrossRef
26.
go back to reference Commissie Modernisering Curatieve Zorg. Gedeelde Zorg: Betere Zorg; Achtergrondstudies Van de Commissie Modernisering Curatieve Zorg. Roosendaal: Ammerlaan Pre-Press, 1994 Commissie Modernisering Curatieve Zorg. Gedeelde Zorg: Betere Zorg; Achtergrondstudies Van de Commissie Modernisering Curatieve Zorg. Roosendaal: Ammerlaan Pre-Press, 1994
27.
go back to reference Groeneveld JF. Specialistenhonoraria. Medisch Contact 1996; 27: 919–21 Groeneveld JF. Specialistenhonoraria. Medisch Contact 1996; 27: 919–21
28.
29.
go back to reference Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analysis. JAMA 1996; 276: 1339–41PubMedCrossRef Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analysis. JAMA 1996; 276: 1339–41PubMedCrossRef
30.
go back to reference Jacobs P, Roos NP. Standard cost lists for healthcare in Canada. Pharmacoeconomics 1999; 15: 551–60PubMedCrossRef Jacobs P, Roos NP. Standard cost lists for healthcare in Canada. Pharmacoeconomics 1999; 15: 551–60PubMedCrossRef
Metadata
Title
Standardisation of Costs
The Dutch Manual for Costing in Economic Evaluations
Authors
Jan B. Oostenbrink
Marc A. Koopmanschap
Frans F. H. Rutten
Publication date
01-06-2002
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 7/2002
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200220070-00002

Other articles of this Issue 7/2002

PharmacoEconomics 7/2002 Go to the issue